How Does Chemotherapy Work for Multiple Myeloma?

Chemotherapy remains a cornerstone in managing multiple myeloma, a cancer of plasma cells in the bone marrow. While newer therapies like immunomodulators and proteasome inhibitors have expanded treatment options, chemotherapy continues to play a vital role—particularly when combined with other approaches. Here’s how it works and where it fits into modern treatment strategies.

How Chemotherapy Drugs Work Against Myeloma

Chemotherapy drugs target myeloma cells primarily by disrupting their rapid growth and division. They do this through distinct mechanisms:

• Alkylating agents like melphalan and cyclophosphamide damage DNA by adding alkyl groups, preventing cancer cells from replicating. This "cross-linking" action is especially effective against rapidly dividing myeloma cells.
• Anthracyclines such as doxorubicin (including its liposomal form) interfere with DNA and RNA synthesis, triggering cell death. Liposomal doxorubicin minimizes heart toxicity by encapsulating the drug for targeted delivery.

It's common for doctors to use a combination of different drugs with various mechanisms of action to treat multiple myeloma. This multi-pronged approach aims to target the cancer cells from different angles, improve effectiveness, and reduce the likelihood of drug resistance. The specific combination of drugs chosen depends on factors like the patient's overall health, the characteristics of their myeloma, and whether they are eligible for a stem cell transplant.

Common Chemotherapy-Based Regimens

Modern regimens pair chemotherapy with other drug classes to improve efficacy:

These combinations leverage chemotherapy’s cell-killing power alongside drugs that enhance immune targeting or disrupt protein recycling in cancer cells. They are often first-line induction therapies for transplant-eligible patients.

When Is Chemotherapy Used in Myeloma?

While chemotherapy was once a primary treatment for multiple myeloma, its role has evolved with the advent of more targeted therapies. Today, it's generally used in specific situations, often in combination with other drugs.

Here are some scenarios where chemotherapy is still used in myeloma treatment:

Before a Stem Cell Transplant (Induction Therapy): This is one of the most common uses. High-dose chemotherapy, particularly with drugs like melphalan, is used to "condition" the patient before an autologous stem cell transplant. The goal is to aggressively reduce the number of myeloma cells in the bone marrow, creating space for the transplanted healthy stem cells to engraft and rebuild the blood-forming system.

As part of Initial (First-Line) Treatment for Newly Diagnosed Myeloma:

• In combination regimens: Chemotherapy drugs are frequently combined with newer targeted agents (like proteasome inhibitors and immunomodulatory drugs) and corticosteroids. This multi-drug approach aims to improve response.
• For patients not eligible for a stem cell transplant: For older or frailer patients who cannot tolerate a stem cell transplant, chemotherapy (often at lower doses) in combination with other drugs can be a mainstay of their initial treatment to control the disease.

For Relapsed or Refractory Myeloma: If myeloma returns after initial treatment (relapsed) or stops responding to ongoing treatment (refractory), chemotherapy might be reintroduced, often in new combinations with other agents, to try and regain control of the disease.

To Manage Symptoms (Palliative Care): In advanced cases, chemotherapy might be used to help reduce pain and manage other symptoms associated with the cancer, aiming to improve the patient's quality of life.

Related questions

• What are the best treatments for Multiple Myeloma?
• Is Velcade a type of chemotherapy?
• Can Darzalex cure Multiple Myeloma?

Side Effects and Management

As chemotherapy targets rapidly dividing cells, it can affect healthy cells and lead to a wide range of side effects. These are carefully managed by the healthcare team.

Common effects of chemotherapy for multiple myeloma include:

• Fatigue
• Nausea
• Low blood counts
• Infection risk
• Hair loss
• Mouth sores

Some side effects can be prevented or managed with supportive care, such as anti-nausea medications (e.g., ondansetron), growth factors (e.g., filgrastim), and infection prevention.

Long-term alkylating agent use raises risks of secondary cancers and lung scarring, necessitating careful monitoring.

Summary

While not a standalone cure, chemotherapy’s synergy with targeted therapies and transplants makes it an important part of myeloma treatment. From induction to relapse, its DNA-damaging action remains a key tool for controlling disease progression and improving survival. Advances like liposomal formulations and enzyme-activated prodrugs continue refining its role, balancing efficacy with patient safety.

Read next

See also:

Related medical questions

• Is Darzalex chemotherapy?
• What’s the difference between Tecvayli and Talvey?
• What is the mechanism of action for Tecvayli (teclistamab-cqyv)?
• Is Tecvayli FDA approved as a multiple myeloma treatment?
• Can Venclexta be used for Multiple Myeloma?
• Where can I find the Tecvayli FDA package insert?
• How is Kyprolis (carfilzomib) administered?
• What is the success rate for Carvykti for Multiple Myeloma?
• What is the success rate of Tecvayli?
• What should I know about the Tecvayli REMS program?
• What is Empliciti (elotuzumab)? and how does Empliciti work?
• What’s the mechanism of action of Carvykti?
• Is Abecma an orphan drug?
• What is Ninlaro used for?

Related support groups

• Multiple Myeloma (24 questions, 54 members)

Medical Disclaimer